A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes
| Autor: | Patrik Dykiel, Tim Heise, Didier Gouet, Jaime A. Davidson, Enrique Romero, Cees J. Tack, Henriette Mersebach, Rolf Jorde, Andreas Liebl, Robert M. Cuddihy |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Advanced and Specialized Nursing
Insulin degludec medicine.medical_specialty Insulin glargine business.industry Endocrinology Diabetes and Metabolism Insulin medicine.medical_treatment Type 2 diabetes Hypoglycemia medicine.disease Insulin aspart Bolus (medicine) Endocrinology Diabetes mellitus Internal medicine Internal Medicine medicine business medicine.drug |
| Zdroj: | Diabetes Care. 34:669-674 |
| ISSN: | 1935-5548 0149-5992 |
| DOI: | 10.2337/dc10-1905 |
| Popis: | OBJECTIVE Insulin degludec/insulin aspart (IDegAsp) is a soluble coformulation of the novel basal analog insulin degludec (IDeg: 70%) and insulin aspart (IAsp: 30%). We compared the safety and efficacy of IDegAsp, an alternative formulation (AF) (55% IDeg and 45% IAsp), and insulin glargine (IGlar) in insulin-naïve subjects with type 2 diabetes inadequately controlled with oral antidiabetic drugs. RESEARCH DESIGN AND METHODS In this 16-week, open-label trial, subjects (mean age 59.1 years, A1C 8.5%, BMI 30.3 kg/m2) were randomized to once-daily IDegAsp (n = 59), AF (n = 59), or IGlar (n = 60), all in combination with metformin. Insulin was administered before the evening meal and dose-titrated to a fasting plasma glucose (FPG) target of 4.0–6.0 mmol/L. RESULTS After 16 weeks, mean A1C decreased in all groups to comparable levels (IDegAsp: 7.0%; AF: 7.2%; IGlar: 7.1%). A similar proportion of subjects achieved A1C CONCLUSIONS In this proof-of-concept trial, once-daily IDegAsp was safe, well tolerated, and provided comparable overall glycemic control to IGlar at similar low rates of hypoglycemia, but better postdinner plasma glucose control. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|